Patheon has entered a definitive agreement to acquire IRIX Pharmaceuticals, a company that specializes in difficult to manufacture Active Pharmaceutical Ingredients (APIs) for drugs from development through commercial launch. The transaction, subject to customary closing conditions, is expected to close in the next 60 days.
 
Patheon secures additional API development and manufacturing services in the U.S., including high-potency (OEL< 30ng/m3) and controlled substances (Schedule 1-4), better meeting customers’ needs. IRIX has a well-established reputation for the optimization of chemical processes and scale up for commercial API manufacturing at sites in Greenville and Florence, S.C.
 
“This is an exciting time at Patheon as we continue to secure important capabilities around the globe to address growing customer needs,” said Lukas Utiger, president, DPx Fine Chemicals and leader of the Patheon OneSource offering. “With this deal we expand our Patheon OneSource™ integrated offering and leverage years of operational experience and scientific excellence at IRIX to complement Patheon’s existing API operations in Europe.”
 
“Combining companies with shared commitments to both scientific excellence and customer service drives industry excellence, and we are excited to become part of the Patheon network,” said Guy Steenrod, chief executive officer, IRIX. “This is a strategic deal that allows us to help customers solve complex challenges with comprehensive, integrated solutions.”